{"id":3161,"date":"2015-11-25T17:48:38","date_gmt":"2015-11-25T17:48:38","guid":{"rendered":"https:\/\/www.therocatest.co.uk\/actualites-et-blogs\/actualites\/"},"modified":"2026-03-30T17:25:13","modified_gmt":"2026-03-30T16:25:13","slug":"actualites","status":"publish","type":"page","link":"https:\/\/www.therocatest.co.uk\/fr\/actualites-et-blogs\/actualites\/","title":{"rendered":"Actualit\u00e9s"},"content":{"rendered":"<div class=\"news-item\">\r\n    septembre 30, 2025\r\n    <img decoding=\"async\" class=\"alignleft\" alt=\"\" src=\"https:\/\/www.therocatest.co.uk\/assets\/nhs.jpg\" \/>\r\n    <h3 class=\"news-title\" style=\"overflow: hidden;\"><a target=\"_self\" href=\"https:\/\/www.therocatest.co.uk\/fr\/news-and-blogs\/news-item\/luclh-lance-un-nouveau-service-de-surveillance-du-cancer-de-lovaire-pour-les-femmes-a-haut-risque\/\">L\u2019UCLH lance un nouveau service de surveillance du cancer de l\u2019ovaire pour les femmes \u00e0 haut risque<\/a><\/h3>\r\n    Le NHS Foundation Trust (UCLH) de l\u2019University College London Hospitals, en collaboration avec la NHS North Central London Cancer Alliance (NCLCA) et GENinCode Plc, devient la premi\u00e8re association hospitali\u00e8re du pays \u00e0 proposer un nouveau service de d\u00e9pistage de surveillance du cancer de l\u2019ovaire (CO) dans le cadre de sa Clinique de canc\u00e9rologie familiale. Le service, conform\u00e9ment aux nouvelles directives du NICE (National Institute for Health and Care Excellence), s\u2019adresse aux femmes pr\u00e9sentant un risque \u00e9lev\u00e9 de cancer de l\u2019ovaire en raison d\u2019alt\u00e9rations h\u00e9r\u00e9ditaires des g\u00e8nes BRCA1 ou BRCA2, qui souhaitent diff\u00e9rer la chirurgie pr\u00e9ventive. \r\n<\/div><div class=\"news-item\">\r\n    d\u00e9cembre 13, 2024\r\n    <img decoding=\"async\" class=\"alignleft\" alt=\"bmj-e1667849106588\" src=\"https:\/\/www.therocatest.co.uk\/assets\/bmj-e1667849106588.jpg\" \/>\r\n    <h3 class=\"news-title\" style=\"overflow: hidden;\"><a target=\"_self\" href=\"https:\/\/www.therocatest.co.uk\/fr\/news-and-blogs\/news-item\/genincode-sassocie-a-genesupport-sa-pour-le-test-roca-en-suisse\/\">GENinCode s\u2019associe \u00e0 Genesupport SA pour le test ROCA\u00ae en Suisse<\/a><\/h3>\r\n    Oxford, Royaume-Uni. GENinCode Plc (AIM : GENI), la soci\u00e9t\u00e9 de g\u00e9n\u00e9tique pr\u00e9dictive sp\u00e9cialis\u00e9e dans la pr\u00e9vention des maladies cardiovasculaires (\u00ab MCV \u00bb) et le risque de cancer de l\u2019ovaire (\u00ab CO \u00bb), annonce son partenariat avec Genesupport SA, partie du r\u00e9seau de laboratoires Sonic Switzerland, afin de permettre un acc\u00e8s national au test ROCA\u00ae. \r\n<\/div><div class=\"news-item\">\r\n    novembre 2, 2022\r\n    <img decoding=\"async\" class=\"alignleft\" alt=\"jmg-e1667849095730\" src=\"https:\/\/www.therocatest.co.uk\/assets\/jmg-e1667849095730.jpg\" \/>\r\n    <h3 class=\"news-title\" style=\"overflow: hidden;\"><a target=\"_self\" href=\"https:\/\/www.therocatest.co.uk\/fr\/news-and-blogs\/news-item\/le-projet-devitement-tardif-du-diagnostic-du-cancer-de-lovaire-aldo-un-programme-pilote-national-de-surveillance-pour-les-femmes-presentant-des-variantes-germinales-pathogenes-da\/\">Le projet d\u2019\u00e9vitement tardif du diagnostic du cancer de l\u2019ovaire (ALDO) ; un programme pilote national de surveillance pour les femmes pr\u00e9sentant des variantes germinales pathog\u00e8nes dans BRCA1 et BRCA2 | Revue de g\u00e9n\u00e9tique m\u00e9dicale (bmj.com)<\/a><\/h3>\r\n    Un programme pilote national de surveillance pour les femmes pr\u00e9sentant des variants germinaux pathog\u00e8nes dans BRCA1 et BRCA2  \r\n<\/div><div class=\"news-item\">\r\n    novembre 2, 2022\r\n    <img decoding=\"async\" class=\"alignleft\" alt=\"uclh-e1667849076226\" src=\"https:\/\/www.therocatest.co.uk\/assets\/uclh-e1667849076226.png\" \/>\r\n    <h3 class=\"news-title\" style=\"overflow: hidden;\"><a target=\"_self\" href=\"https:\/\/www.therocatest.co.uk\/fr\/news-and-blogs\/news-item\/des-recherches-a-luclh-montrent-que-la-surveillance-du-cancer-de-lovaire-chez-les-femmes-a-haut-risque-est-benefique-university-college-london-hospitals-nhs-foundation-trust\/\">Des recherches \u00e0 l\u2019UCLH montrent que la surveillance du cancer de l\u2019ovaire chez les femmes \u00e0 haut risque est b\u00e9n\u00e9fique : University College London Hospitals NHS Foundation Trust<\/a><\/h3>\r\n    Des recherches \u00e0 l\u2019UCLH montrent que la surveillance du cancer de l\u2019ovaire chez les femmes \u00e0 haut risque est b\u00e9n\u00e9fique : University College London Hospitals NHS Foundation Trust\r\n<\/div><div class=\"news-item\">\r\n    novembre 2, 2022\r\n    <img decoding=\"async\" class=\"alignleft\" alt=\"eveappeal-e1667849059208\" src=\"https:\/\/www.therocatest.co.uk\/assets\/eveappeal-e1667849059208.jpg\" \/>\r\n    <h3 class=\"news-title\" style=\"overflow: hidden;\"><a target=\"_self\" href=\"https:\/\/www.therocatest.co.uk\/fr\/news-and-blogs\/news-item\/un-suivi-regulier-du-cancer-de-lovaire-sest-avere-benefique-chez-les-femmes-presentant-des-alterations-genetiques-brca-lappel-deve\/\">Un suivi r\u00e9gulier du cancer de l\u2019ovaire s\u2019est av\u00e9r\u00e9 b\u00e9n\u00e9fique chez les femmes pr\u00e9sentant des alt\u00e9rations g\u00e9n\u00e9tiques BRCA | L\u2019Appel d\u2019Eve<\/a><\/h3>\r\n    De nouvelles recherches ont \u00e9t\u00e9 publi\u00e9es dans le dernier num\u00e9ro du Journal of Medical Genetics et ont montr\u00e9 que surveiller r\u00e9guli\u00e8rement les femmes ayant une alt\u00e9ration g\u00e9n\u00e9tique BRCA apporte des b\u00e9n\u00e9fices. Ce travail a \u00e9t\u00e9 financ\u00e9 par la North Central London Cancer Alliance et Abcodia, et dirig\u00e9 par des chercheurs de l\u2019UCLH. Il est n\u00e9 du proc\u00e8s FOCCS au Royaume-Uni, soutenu par The Eve Appeal.  \r\n<\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":42,"featured_media":0,"parent":3077,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_eb_attr":"","footnotes":""},"class_list":["post-3161","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.therocatest.co.uk\/fr\/wp-json\/wp\/v2\/pages\/3161"}],"collection":[{"href":"https:\/\/www.therocatest.co.uk\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.therocatest.co.uk\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.therocatest.co.uk\/fr\/wp-json\/wp\/v2\/users\/42"}],"replies":[{"embeddable":true,"href":"https:\/\/www.therocatest.co.uk\/fr\/wp-json\/wp\/v2\/comments?post=3161"}],"version-history":[{"count":1,"href":"https:\/\/www.therocatest.co.uk\/fr\/wp-json\/wp\/v2\/pages\/3161\/revisions"}],"predecessor-version":[{"id":3162,"href":"https:\/\/www.therocatest.co.uk\/fr\/wp-json\/wp\/v2\/pages\/3161\/revisions\/3162"}],"up":[{"embeddable":true,"href":"https:\/\/www.therocatest.co.uk\/fr\/wp-json\/wp\/v2\/pages\/3077"}],"wp:attachment":[{"href":"https:\/\/www.therocatest.co.uk\/fr\/wp-json\/wp\/v2\/media?parent=3161"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}